Intraocular lymphoma: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(50 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}                                                                 
{{SI}}                                                                 
{{CMG}} {{AE}} {{MV}}  
{{CMG}} {{AE}} {{Fs}}, {{MV}}  
   
   
{{SK}}  PIOL  
{{SK}}  PIOL; Ocular Lymphoma; Primary central nervous system ocular lymphoma
   
   
==Overview==
==Overview==
'''Intraocular lymphoma''' (also known as "PIOL") is a rare subtype of primary central nervous system lymphoma. Intraocular lymphoma may affect the eye secondarily from a metastasis from a non-ocular tumor or may arise within the eye primarily. According to the World Health Organization (WHO) classification, intraocular lymphomas are most commonly a diffuse large B-cell immunohistologic subtype of non-Hodgkin's lymphoma. The most common symptoms of intraocular lymphoma is blurred or decreased vision. In the majority of patients, central nervous system involvement, only accounts for 20% of primary central nervous system lymphomas. The median age at diagnosis among patients with intraocular lymphoma is between 50-60 years.  The pathogenesis of intraocular lymphoma is characterized by the affection of the sub-retinal pigment epithelium, which is normally involved in the light absorption.  On fluorescein angiography, findings may reveal "leopard spot" patterns due to sub-retinal pigment epithelium infiltrates that stain early and progressively or mottling of the sub-retinal pigment epithelium due to hyper- and hypo-fluorescent window defects.  The initial therapy for patients with intraocular lymphoma is corticosteroids.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
'''Intraocular lymphoma''' is a rare subtype of [[primary central nervous system lymphoma]]. Intraocular lymphoma may affect the eye secondarily from [[metastasis]] from a non-[[ocular]] tumor or may arise within the eye primarily. According to the [[World Health Organization]] (WHO) classification, intraocular lymphomas are most commonly a [[Diffuse large B cell lymphoma|diffuse large B-cell]] immunohistologic subtype of [[Non-Hodgkin lymphoma|non-Hodgkin's lymphoma]]. The most common symptoms of intraocular lymphoma are [[Blurred vision|blurred]] or decreased vision. In the majority of patients, [[central nervous system]] involvement only accounts for 20% of [[Primary central nervous system lymphoma|primary central nervous system lymphomas]]. The median age at diagnosis among patients with intraocular lymphoma is between 50-60 years.  The [[pathogenesis]] of intraocular lymphoma is characterized by the affection of the sub-[[retinal pigment epithelium]], which is normally involved in the light absorption.  On fluorescein angiography, findings may reveal "leopard spot" patterns due to sub-[[retinal pigment epithelium]] infiltrates that [[stain]] early and progressively or [[mottling]] of the sub-[[retinal pigment epithelium]] due to hyper- and hypo-[[fluorescent]] window defects.  The initial therapy for patients with intraocular lymphoma is [[Corticosteroid|corticosteroids]].


==Historical Perspective==
==Historical Perspective==
*Intraocular lymphoma was first discovered by Samuel Wilks, a British physician, in 1856.
*Intraocular lymphoma was first discovered by Samuel Wilks, a British physician, in 1856.<ref name="sci">Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci. 2006 Feb. 331(2):79-83.</ref>


==Classification==
==Classification==
*According to the World Health Organization (WHO) classification, intraocular lymphomas are most commonly a diffuse large B-cell immunohistologic subtype of non-Hodgkin's lymphoma
Intraocular lymphoma may be classified according to its location into 2 subtypes:<ref name="CouplandDamato2008">{{cite journal|last1=Coupland|first1=Sarah E|last2=Damato|first2=Bertil|title=Understanding intraocular lymphomas|journal=Clinical & Experimental Ophthalmology|volume=36|issue=6|year=2008|pages=564–578|issn=14426404|doi=10.1111/j.1442-9071.2008.01843.x}}</ref>
*Primary central nervous system lymphoma may be classified into 5 subtypes:
 
:*Primary cerebral lymphoma
*[[Retinal]]
:*Primary leptomeningeal lymphoma
**Retinal
:*'''Primary intraocular lymphoma'''
**Vitreoretinal
:*Primary spinal lymphoma
**[[Vitreous|Vitreal]]
:*Neurolymphomatosis
*[[Uvea (anatomy)|Uveal]]
**[[Iris|Iridal]]
**[[Ciliary Muscle|Ciliary]]
**[[Choroidal]]
 
 
{{Family tree/start}}
{{Family tree | | | | | | | | | | | | | | | | A10 | | | | | | | | | | | | | | | | | | A10=Intraocular lymphoma}}
{{Family tree | | | | | | | |,|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|.| | | | | | | | | }}
{{Family tree | | | | | | | B10 | | | | | | | | | | | | | | | | B11 | | | | | | | | B10=Retinal|B11=Uveal}}
{{Family tree | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | }}
{{Family tree | C10 | | | | C11 | | | | C12 | | | | C13 | | | | C14 | | | | C15 | | C10=Retinal|C11=Vitreoretinal|C12=Vitreal|C13=Iridal|C14=Ciliary|C15=Choroidal}}
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|^|-|.| }}
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | D10 | | D11| D10=Primary|D11=Secondary}}
{{Family tree/end}}
 


==Pathophysiology==
==Pathophysiology==
*Intraocular lymphoma is characterized as a secondary central nervous system lymphoma that mainly affects the optic nerve and the eye.  
 
*The pathogenesis of intraocular lymphoma is characterized by the affection of the sub-retinal pigment epithelium, which is normally involved in the light absorption.
* Intraocular lymphoma arises from [[B cell]], which are normally involved in [[immune system]].
*Genes associated with the development of intraocular lymphoma, include:  
 
:*C-MYC gene
*Intraocular lymphoma can be either [[Primary central nervous system lymphoma|primary]] or secondary central nervous system lymphoma (oculocerebral lymphoma) that mainly affects the [[optic nerve]] and the eye.<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>
:*CCND1 gene
*The [[pathogenesis]] of intraocular lymphoma is characterized by the affection of the sub-[[retinal pigment epithelium]], which is normally involved in the light absorption.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*On gross pathology, characteristic findings of intraocular lymphoma, include:
*[[Gene|Genes]] associated with the development of intraocular lymphoma, include:<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>
:*No remarkable findings
 
*On microscopic histopathological analysis, characteristic findings of intraocular lymphoma, include:
:*[[C-myc|C-MYC gene]]
:*Marginal zone (52%)
:*[[CCND1|CCND1 gene]]
 
*On microscopic histopathological analysis, characteristic findings of intraocular lymphoma, include:<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>
 
:*[[Marginal zone]] (52%)
:*Follicular (23%)
:*Follicular (23%)
:*Atypical lymphocytes (gold standard)
:*[[Atypical lymphocytes]] ([[Gold standard (test)|gold standard]])
:*Elevated interleukin [[IL-10]]. According to the [[World Health Organization]] (WHO) classification, intraocular lymphomas are most commonly a [[Diffuse large B-cell lymphoma|diffuse large B-cell]] immunohistologic subtype of [[Non-Hodgkin lymphoma|non-Hodgkin's lymphoma]].<ref name="PIOL" />


==Causes==
==Causes==
Line 37: Line 57:


==Differentiating Intraocular Lymphoma from Other Diseases==
==Differentiating Intraocular Lymphoma from Other Diseases==
*Intraocular lymphoma must be differentiated from other diseases that cause chronic loss of vision, or headaches, such as:
*Intraocular lymphoma must be differentiated from other diseases that cause chronic [[loss of vision]], or [[headaches]], such as:<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref><ref name="SenBodaghi2009">{{cite journal|last1=Sen|first1=H. Nida|last2=Bodaghi|first2=Bahram|last3=Hoang|first3=Phuc Le|last4=Nussenblatt|first4=Robert|title=Primary Intraocular Lymphoma: Diagnosis and Differential Diagnosis|journal=Ocular Immunology and Inflammation|volume=17|issue=3|year=2009|pages=133–141|issn=0927-3948|doi=10.1080/09273940903108544}}</ref>
:*Ocular metastasis (80% of all ocular lesions)
 
:* Ocular [[metastasis]] (most common)
:*Pigmented [[nevi]]
:*[[Congenital]] [[hypertrophy]] of the [[retinal pigment epithelium]]
:* Optic disc melanocytoma
:*[[Hypertrophy]] of the [[retinal pigment epithelium]]
:*[[Hyperplasia]] of [[retinal pigment epithelium]]
:*[[Choroidal]] [[hemangioma]]
:*[[Choroidal]] [[metastasis]]
:*[[Choroidal]] [[osteoma]]
:* Peripheral [[exudative]] hemorrhagic chorioretinopathy
:*[[Choroidal]] [[hemorrhage]]
:* Hemorrhagic detachment of [[retina]] and [[retinal pigment epithelium]]
:*[[Posterior]] [[nodular]] [[scleritis]]
:* Intraocular [[leiomyoma]]
:*[[Adenoma]] of [[retinal pigment epithelium]]
:*[[Retinoblastoma]]
:* Uveal [[metastases]]
:*[[Choroidal]] detachment
:*[[Choroidal]] [[cyst]]
:* Uveal [[neurofibroma]]
:* Uveal [[schwannoma]]
:*Choroidal hemangioma
:*Choroidal hemangioma
:*Vitrous lymphoma
:*Vitrous lymphoma
Line 44: Line 85:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
* The prevalence of intraocular lymphoma remains unknown.  
 
=== Prevalence ===
 
* The [[prevalence]] of intraocular lymphoma remains unknown.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref><ref name="MochizukiSingh2009">{{cite journal|last1=Mochizuki|first1=Manabu|last2=Singh|first2=Arun D.|title=Epidemiology and Clinical Features of Intraocular Lymphoma|journal=Ocular Immunology and Inflammation|volume=17|issue=2|year=2009|pages=69–72|issn=0927-3948|doi=10.1080/09273940902957305}}</ref>
 
===Age===
===Age===
*Intraocular lymphoma is more commonly observed among patients aged 50 to 60 years old.
*Intraocular lymphoma is more commonly observed among patients aged 50 to 60 years old.
*Intraocular lymphoma is more commonly observed among middle aged adults.
 
===Gender===
===Gender===
*Males are more commonly affected with intraocular lymphoma than females.  
*Males are more commonly affected with intraocular lymphoma than females.
 
===Race===
===Race===
*There is no racial predilection for intraocular lymphoma.
*There is no [[racial]] predilection for intraocular lymphoma.


==Risk Factors==
==Risk Factors==
*Common risk factors in the development of intraocular lymphoma, include:
*Common [[risk factors]] in the development of intraocular lymphoma, include:<ref name="ShenHerbort2001">{{cite journal|last1=Shen|first1=De Fen|last2=Herbort|first2=Carl P|last3=Tuaillon|first3=Nadine|last4=Buggage|first4=Ronald R|last5=Egwuagu|first5=Charles E|last6=Chan|first6=Chi-Chao|title=Detection of Toxoplasma Gondii DNA in Primary Intraocular B-Cell Lymphoma|journal=Modern Pathology|volume=14|issue=10|year=2001|pages=995–999|issn=0893-3952|doi=10.1038/modpathol.3880424}}</ref><ref name="pmid14971583">{{cite journal |vauthors=Chan CC |title=Molecular pathology of primary intraocular lymphoma |journal=Trans Am Ophthalmol Soc |volume=101 |issue= |pages=275–92 |date=2003 |pmid=14971583 |pmc=1358994 |doi= |url=}}</ref>
:*Toxoplasma gondii infection
 
:*[[Toxoplasma gondii]] infection
:*[[EBV infection]]
:*HHV8 infection


== Natural History, Complications and Prognosis==
== Natural History, Complications and Prognosis==
*The majority of patients with intraocular lymphoma are symptomatic at the time of diagnosis.  
*The majority of patients with intraocular lymphoma are [[symptomatic]] at the time of diagnosis.
*Early clinical features include symptoms of a non-resolving uveitis, and blurred vision.
*Early clinical features include symptoms of a non-resolving uveitis, and blurred vision.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*If left untreated, patients with intraocular lymphoma may progress to develop complete vision loss.  
*If left untreated, patients with intraocular lymphoma may progress to develop complete vision loss.  
*Common complications of intraocular lymphoma, include:
*Common complications of intraocular lymphoma, include:<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>
*Prognosis is generally poor, and the median survival rate of patients with intraocular lymphoma is approximately
:*Blindness
:*Radiation-induced retinopathy
:*Neovascular glaucoma
*Prognosis is generally good, and the 5-year survival for patients with intraocular lymphoma is between 65-80%.<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>


== Diagnosis ==
== Diagnosis ==
=== Symptoms ===
=== History and Symptoms ===
*Symptoms of intraocular lymphoma may include the following:
*Common symptoms of intraocular lymphoma include:<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref><ref name="CouplandDamato20082">{{cite journal|last1=Coupland|first1=Sarah E|last2=Damato|first2=Bertil|title=Understanding intraocular lymphomas|journal=Clinical & Experimental Ophthalmology|volume=36|issue=6|year=2008|pages=564–578|issn=14426404|doi=10.1111/j.1442-9071.2008.01843.x}}</ref>
 
:* Burning of the eye
:* Burning of the eye
:* Redness of the eye
:* Redness of the eye
:* [[Blurred vision]]
:*Visual field defect
:* [[Photophobia]] or sensitivity to light
:*[[Blurred vision]]
:*[[Photophobia]] or sensitivity to light
:* Eye pain
:* Eye pain
:* [[Floaters]] (which are dark spots that float in the visual field)
:*[[Floaters]]  
:* Headache
:* Headache
*Severe symptoms of intraocular lymphoma, may include:
:*Aphasia
:*Seizures
:*Ataxia
:*Visual field defect


=== Physical Examination ===
=== Physical Examination ===
*Patients with intraocular lymphoma usually appear pale or malnourished.  
*Patients with intraocular lymphoma usually appear pale or malnourished.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*Physical examination may be remarkable for:
*Physical examination may be remarkable for:
:*Decreased visual acuity (most common)
:*Decreased visual acuity (most common)
:*Irregular pupil
:*Irregular pupil
:*Increased lacrimation
:*Increased lacrimation
:*Eye redness
:*[[Eye redness]]
:*Increased intraocular pressure
:*Increased intraocular pressure


Line 93: Line 142:
   
   
===Imaging Findings===
===Imaging Findings===
*Magnetic resonance image (MRI) is the imaging modality of choice for patients with intraocular lymphoma.  
*Magnetic resonance image (MRI) is the imaging modality of choice for patients with intraocular lymphoma.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*On MRI, characteristic findings of intraocular lymphoma, include:
*On MRI, characteristic findings of intraocular lymphoma, include:<ref name="wiki">Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma</ref>
:*Fat suppressed T2 and post-contrast T1 weighted images, with thin slice thickness and a reduced FOV is ideal, and should include the cavernous sinuses.
:*Fat suppressed T2 and post-contrast T1 weighted images, with thin slice thickness and a reduced FOV is ideal, and should include the cavernous sinuses.
:*T1: isointense to muscle 8
:*T1: isointense to muscle 8
Line 102: Line 151:
== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*The initial therapy for intraocular lymphoma is corticosteroids.  
*The initial therapy for intraocular lymphoma is corticosteroids.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*Other medical therapies for intraocular lymphoma, may include:
*Other medical therapies for intraocular lymphoma, may include:<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
:*Methotrexate
:*Intravitreal rituximab
:*Localized external beam radiation therapy (EBRT)


=== Surgery ===
=== Surgery ===
*Surgery is the mainstay of therapy for intraocular lymphoma.
*Surgery is the mainstay of therapy for intraocular lymphoma.
   
   
=== Prevention ===
=== Primary Prevention ===
*There are no primary preventive measures available for intraocular lymphoma.
*There are no primary preventive measures available for intraocular lymphoma.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
*Once diagnosed and successfully treated, patients with intraocular lymphoma are followed-up periodically every 3, 6, or 12 months.
*Once diagnosed and successfully treated, patients with intraocular lymphoma are followed-up periodically every 3, 6, or 12 months.
*The average relapse rate among patients with intraocular lymphoma is 2 years.<ref name="PIOL">Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15</ref>
=== Secondary Prevention ===


==References==
==References==
Line 116: Line 171:
   
   
[[Category: Oncology]]
[[Category: Oncology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Ophthalmology]]
[[Category:Hematology]]

Latest revision as of 14:15, 18 September 2019

WikiDoc Resources for Intraocular lymphoma

Articles

Most recent articles on Intraocular lymphoma

Most cited articles on Intraocular lymphoma

Review articles on Intraocular lymphoma

Articles on Intraocular lymphoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Intraocular lymphoma

Images of Intraocular lymphoma

Photos of Intraocular lymphoma

Podcasts & MP3s on Intraocular lymphoma

Videos on Intraocular lymphoma

Evidence Based Medicine

Cochrane Collaboration on Intraocular lymphoma

Bandolier on Intraocular lymphoma

TRIP on Intraocular lymphoma

Clinical Trials

Ongoing Trials on Intraocular lymphoma at Clinical Trials.gov

Trial results on Intraocular lymphoma

Clinical Trials on Intraocular lymphoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Intraocular lymphoma

NICE Guidance on Intraocular lymphoma

NHS PRODIGY Guidance

FDA on Intraocular lymphoma

CDC on Intraocular lymphoma

Books

Books on Intraocular lymphoma

News

Intraocular lymphoma in the news

Be alerted to news on Intraocular lymphoma

News trends on Intraocular lymphoma

Commentary

Blogs on Intraocular lymphoma

Definitions

Definitions of Intraocular lymphoma

Patient Resources / Community

Patient resources on Intraocular lymphoma

Discussion groups on Intraocular lymphoma

Patient Handouts on Intraocular lymphoma

Directions to Hospitals Treating Intraocular lymphoma

Risk calculators and risk factors for Intraocular lymphoma

Healthcare Provider Resources

Symptoms of Intraocular lymphoma

Causes & Risk Factors for Intraocular lymphoma

Diagnostic studies for Intraocular lymphoma

Treatment of Intraocular lymphoma

Continuing Medical Education (CME)

CME Programs on Intraocular lymphoma

International

Intraocular lymphoma en Espanol

Intraocular lymphoma en Francais

Business

Intraocular lymphoma in the Marketplace

Patents on Intraocular lymphoma

Experimental / Informatics

List of terms related to Intraocular lymphoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: PIOL; Ocular Lymphoma; Primary central nervous system ocular lymphoma

Overview

Intraocular lymphoma is a rare subtype of primary central nervous system lymphoma. Intraocular lymphoma may affect the eye secondarily from metastasis from a non-ocular tumor or may arise within the eye primarily. According to the World Health Organization (WHO) classification, intraocular lymphomas are most commonly a diffuse large B-cell immunohistologic subtype of non-Hodgkin's lymphoma. The most common symptoms of intraocular lymphoma are blurred or decreased vision. In the majority of patients, central nervous system involvement only accounts for 20% of primary central nervous system lymphomas. The median age at diagnosis among patients with intraocular lymphoma is between 50-60 years. The pathogenesis of intraocular lymphoma is characterized by the affection of the sub-retinal pigment epithelium, which is normally involved in the light absorption. On fluorescein angiography, findings may reveal "leopard spot" patterns due to sub-retinal pigment epithelium infiltrates that stain early and progressively or mottling of the sub-retinal pigment epithelium due to hyper- and hypo-fluorescent window defects. The initial therapy for patients with intraocular lymphoma is corticosteroids.

Historical Perspective

  • Intraocular lymphoma was first discovered by Samuel Wilks, a British physician, in 1856.[1]

Classification

Intraocular lymphoma may be classified according to its location into 2 subtypes:[2]


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intraocular lymphoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retinal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uveal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retinal
 
 
 
Vitreoretinal
 
 
 
Vitreal
 
 
 
Iridal
 
 
 
Ciliary
 
 
 
Choroidal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary
 
Secondary


Pathophysiology

  • Intraocular lymphoma can be either primary or secondary central nervous system lymphoma (oculocerebral lymphoma) that mainly affects the optic nerve and the eye.[3]
  • The pathogenesis of intraocular lymphoma is characterized by the affection of the sub-retinal pigment epithelium, which is normally involved in the light absorption.[4]
  • Genes associated with the development of intraocular lymphoma, include:[3]
  • On microscopic histopathological analysis, characteristic findings of intraocular lymphoma, include:[3]

Causes

  • There are no established causes of intraocular lymphoma.

Differentiating Intraocular Lymphoma from Other Diseases

Epidemiology and Demographics

Prevalence

Age

  • Intraocular lymphoma is more commonly observed among patients aged 50 to 60 years old.

Gender

  • Males are more commonly affected with intraocular lymphoma than females.

Race

  • There is no racial predilection for intraocular lymphoma.

Risk Factors

Natural History, Complications and Prognosis

  • The majority of patients with intraocular lymphoma are symptomatic at the time of diagnosis.
  • Early clinical features include symptoms of a non-resolving uveitis, and blurred vision.[4]
  • If left untreated, patients with intraocular lymphoma may progress to develop complete vision loss.
  • Common complications of intraocular lymphoma, include:[3]
  • Blindness
  • Radiation-induced retinopathy
  • Neovascular glaucoma
  • Prognosis is generally good, and the 5-year survival for patients with intraocular lymphoma is between 65-80%.[3]

Diagnosis

History and Symptoms

  • Common symptoms of intraocular lymphoma include:[4][9]

Physical Examination

  • Patients with intraocular lymphoma usually appear pale or malnourished.[4]
  • Physical examination may be remarkable for:
  • Decreased visual acuity (most common)
  • Irregular pupil
  • Increased lacrimation
  • Eye redness
  • Increased intraocular pressure

Laboratory Findings

  • There are no specific laboratory findings associated with intraocular lymphoma.

Imaging Findings

  • Magnetic resonance image (MRI) is the imaging modality of choice for patients with intraocular lymphoma.[4]
  • On MRI, characteristic findings of intraocular lymphoma, include:[3]
  • Fat suppressed T2 and post-contrast T1 weighted images, with thin slice thickness and a reduced FOV is ideal, and should include the cavernous sinuses.
  • T1: isointense to muscle 8
  • T2: hyperintense to muscle, hypointense to fat
  • T1 C+ (GAD): enhancement present but variable

Treatment

Medical Therapy

  • The initial therapy for intraocular lymphoma is corticosteroids.[4]
  • Other medical therapies for intraocular lymphoma, may include:[4]
  • Methotrexate
  • Intravitreal rituximab
  • Localized external beam radiation therapy (EBRT)

Surgery

  • Surgery is the mainstay of therapy for intraocular lymphoma.

Primary Prevention

  • There are no primary preventive measures available for intraocular lymphoma.[4]
  • Once diagnosed and successfully treated, patients with intraocular lymphoma are followed-up periodically every 3, 6, or 12 months.
  • The average relapse rate among patients with intraocular lymphoma is 2 years.[4]

Secondary Prevention

References

  1. ↑ Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci. 2006 Feb. 331(2):79-83.
  2. ↑ Coupland, Sarah E; Damato, Bertil (2008). "Understanding intraocular lymphomas". Clinical & Experimental Ophthalmology. 36 (6): 564–578. doi:10.1111/j.1442-9071.2008.01843.x. ISSN 1442-6404.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Intraocular lymphoma. Wikipedia. https://en.wikipedia.org/wiki/Intraocular_lymphoma
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 Hanson JA, Alexandru D and Bota DA: The evaluation and treatment of primary intraocular lymphoma. journal of Cancer Therapeutics and Research 2013, 2:15 http://dx.doi.org/10.7243/2049-7962-2-15
  5. ↑ Sen, H. Nida; Bodaghi, Bahram; Hoang, Phuc Le; Nussenblatt, Robert (2009). "Primary Intraocular Lymphoma: Diagnosis and Differential Diagnosis". Ocular Immunology and Inflammation. 17 (3): 133–141. doi:10.1080/09273940903108544. ISSN 0927-3948.
  6. ↑ Mochizuki, Manabu; Singh, Arun D. (2009). "Epidemiology and Clinical Features of Intraocular Lymphoma". Ocular Immunology and Inflammation. 17 (2): 69–72. doi:10.1080/09273940902957305. ISSN 0927-3948.
  7. ↑ Shen, De Fen; Herbort, Carl P; Tuaillon, Nadine; Buggage, Ronald R; Egwuagu, Charles E; Chan, Chi-Chao (2001). "Detection of Toxoplasma Gondii DNA in Primary Intraocular B-Cell Lymphoma". Modern Pathology. 14 (10): 995–999. doi:10.1038/modpathol.3880424. ISSN 0893-3952.
  8. ↑ Chan CC (2003). "Molecular pathology of primary intraocular lymphoma". Trans Am Ophthalmol Soc. 101: 275–92. PMC 1358994. PMID 14971583.
  9. ↑ Coupland, Sarah E; Damato, Bertil (2008). "Understanding intraocular lymphomas". Clinical & Experimental Ophthalmology. 36 (6): 564–578. doi:10.1111/j.1442-9071.2008.01843.x. ISSN 1442-6404.
Retrieved from "https://www.wikidoc.org/index.php?title=Intraocular_lymphoma&oldid=1582092"